Artiam Bio Inc.

Artiam Bio, Inc. is a biotechnology company that is developing second generation type 1 cannabinoid receptor (CB1) antagonists to treat significant diseases. We are accelerating innovation to bring safe and effective treatment options. We are focused on leveraging our core competency in cannabinoid receptor pharmacology to develop novel, small molecule drugs to help people whose lives are dramatically affected by severe diseases.